Abstract
Venous thromboembolism (VTE) is a major public health issue, with a high incidence in hospitalised patients. Furthermore, many VTE events are preventable with appropriate thromboprophylaxis. Medical thromboprophylaxis usually comprises heparins, while warfarin has been the mainstay of long term anticoagulation for many years. Both drugs are limited by their narrow therapeutic index and the need for regular monitoring. The introduction of low molecular weight heparins and fondaparinux has overcome some of these shortfalls but their use remains restricted by requisite parenteral administration. There is a clear need for new anticoagulants with predictable pharmacokinetics and anticoagulant effect. To this end, 2 new agents; dabigatran and rivaroxaban, have recently been licensed for use in orthopaedic thromboprophylaxis. This review discusses the limitations of traditional anticoagulants, and summarises the development and clinical studies pertaining to the use of 3 new targeted anticoagulants: idraparinux, rivaroxaban and dabigatran in VTE, in addition to the limitations of these novel agents.
Keywords: Venous thromboembolism, thromboprophylaxis, anticoagulation, idraparinux, rivaroxaban, dabigatran
Current Vascular Pharmacology
Title: New Anticoagulants for Prevention and Treatment of Venous Thromboembolism
Volume: 8 Issue: 3
Author(s): Lara N. Roberts and Roopen Arya
Affiliation:
Keywords: Venous thromboembolism, thromboprophylaxis, anticoagulation, idraparinux, rivaroxaban, dabigatran
Abstract: Venous thromboembolism (VTE) is a major public health issue, with a high incidence in hospitalised patients. Furthermore, many VTE events are preventable with appropriate thromboprophylaxis. Medical thromboprophylaxis usually comprises heparins, while warfarin has been the mainstay of long term anticoagulation for many years. Both drugs are limited by their narrow therapeutic index and the need for regular monitoring. The introduction of low molecular weight heparins and fondaparinux has overcome some of these shortfalls but their use remains restricted by requisite parenteral administration. There is a clear need for new anticoagulants with predictable pharmacokinetics and anticoagulant effect. To this end, 2 new agents; dabigatran and rivaroxaban, have recently been licensed for use in orthopaedic thromboprophylaxis. This review discusses the limitations of traditional anticoagulants, and summarises the development and clinical studies pertaining to the use of 3 new targeted anticoagulants: idraparinux, rivaroxaban and dabigatran in VTE, in addition to the limitations of these novel agents.
Export Options
About this article
Cite this article as:
N. Roberts Lara and Arya Roopen, New Anticoagulants for Prevention and Treatment of Venous Thromboembolism, Current Vascular Pharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157016110791112232
DOI https://dx.doi.org/10.2174/157016110791112232 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design of Bioartificial Pancreas with Functional Micro/Nano-Based Encapsulation of Islets
Current Pharmaceutical Biotechnology Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design Efficacy and Safety Evaluation of Fixed Dose Combination of Cefepime and Amikacin in Comparison with Cefepime Alone in Treatment of Nosocomial Pneumonia Patients
Current Clinical Pharmacology Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Cardiovascular & Hematological Disorders-Drug Targets Living Heart Valve and Small-Diameter Artery Substitutes - An Emerging Field for Intellectual Property Development
Recent Patents on Biotechnology Strategies to Direct Angiogenesis within Scaffolds for Bone Tissue Engineering
Current Pharmaceutical Design Periodontitis and Redox Status: A Review
Current Pharmaceutical Design Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury: First Case-Controlled Study from Iran
Current Drug Safety Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Age-related Vascular Differences among Patients Suffering from Multiple Sclerosis
Current Neurovascular Research Dry Eye Disease: Present Challenges in the Management and Future Trends
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Obesity and Insulin Resistance: Associations with Chronic Inflammation, Genetic and Epigenetic Factors
Current Medicinal Chemistry The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Brain Hyperthermia During Physiological and Pathological Conditions: Causes, Mechanisms, and Functional Implications
Current Neurovascular Research Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Aldosterone and Resistant Hypertension
Current Hypertension Reviews